Effect of Repaglinide on Postprandial Lipemia in Type 2 Diabetes

Novo Nordisk A/S51 enrolled

Overview

This trial is conducted in the United States of America (USA). The aim of this trial is to compare the effect of repaglinide on postprandial lipemia in subjects with type 2 diabetes.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Diabetes Diabetes Mellitus, Type 2

Interventions

repaglinideDRUG

Dose individually adjusted and conducted according to labeling

glyburideDRUG

Dose individually adjusted and conducted according to labeling

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Newly diagnosed patients with type 2 diabetes currently treated with diet and exercise alone (HbA1c below 10%) * Subjects with type 2 diabetes treated with sulphonylurea (HbA1c below 8.5%) * Males or non-pregnant, non-lactating females * Subjects should have normal renal function Exclusion Criteria: * Type 1 or other specific causes of diabetes * Marked symptomatic diabetes * Uncontrolled treated/untreated hypertension * Known or suspected allergy to the trial products or related products

Locations (1)

Novo Nordisk Investigational Site

Houston, Texas, United States

Outcomes

Primary Outcomes

Triglyceride levels post standardised fat tolerance test

Secondary Outcomes

Incidence of hypoglycemic episodes

Change in HbA1c (glycosylated haemoglobin A1c)

Change in FPG (fasting plasma glucose)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.